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0.25 m/sec) (p=NS).
Conclusion: Long-term combined HRT has no favorable effects on large artery compli-
ance in hypertensive postmenopausal women. In the same population, abnormal circa-
dian BP variability does not attenuate the estrogen-induced alterations in arterial
elasticity.
1160-169 Short Term Estrogen Replacement Therapy Improves 
Cardiovascular Autonomic Response in 
Postmenopausal Women: A Double-Blind Randomized 
Placebo Controlled Trial
Juan C. Guzman, Ronald G. Garcia, Juan P. Casas, Luis A. Diaz, Patricio Lopez-
Jaramillo, Carlos A. Morillo, Carlos A. Morillo, Fundacion Cardiovascular de Colombia, 
Floridablanca, Colombia, Universidad Autonoma de Bucaramanga, Bucaramanga, 
Colombia
BACKGROUND: Estrogen deficit may lead to cardiac autonomic function imbalance in
the postmenopausal women that may potentially increase cardiovascular risk. The physi-
ological mechanism by which estrogen replacement therapy (ERT) regulates the auto-
nomic nervous system in postmenopausal women remains unclear.
METHODS: Thirty nine patients aged 45-65 years with a previous total hysterectomy and
amenorrhea for 1 year prior to the surgery were enrolled in this prospective, randomized
double-blind, placebo-controlled trial. Women with obesity, cardiovascular, neurological
or metabolic disease were excluded. Conjugated estrogens were administered at a dose
of 0.625 mg daily during 12 weeks in 19 patients (52.6± 7.1 years), and matched placebo
in 20 women (53.8± 5.4 years). Cardiopulmonary and arterial baroreceptor response
was determined after 3 months of treatment in both groups. Arterial baroreflex sensitivity
(BRS) was determined after the intravenous bolus administration of vasoactive sub-
stances (phenylephrine 150 mcg, sodium nitroprussiate,100 mcg). Cardiopulmonary
baroreflex response(CBR) was calculated using venous occlusion plethysmography by
determining forearm blood flow changes (FBF) and peripheral vascular resistance (PVR)
to –10mmHg lower-body negative pressure (LBNP). All measurements were performed
between 8am-12m. All signals were analyzed with the winCPRS software (Absolutely
Aliens, Finland).
RESULTS: A significant increase in BRS was found after 3 months of ERT compared
with placebo; Phenylephrin; 9.28 ±3.72 vs 15.93±10.22, p=0.09 and Nitroprussiate;
6.7±2.73 vs. 12.68±8.40, p<0.01. During LBNP a higher FBF (1.10±0.39 vs.
0.81±0.15,p<0.05) was associated with lower PVR (97.7±32.5 vs. 129.4±43.5, p<0.05) in
the group receiving ERT compared to the placebo group.
CONCLUSIONS: Short term ERT (3 months) may modulate cardiovascular autonomic
responses leading to reduced sympathetic activity (PVR) and improving cardiovagal
response by increasing arterial baroreflex sensitivity in postmenopausal women. (Col-
ciencias Grant: 6566-04-11788)
1160-170 Irbesartan Significantly Reduces C-Reactive Protein 
After One Month of Therapy in Unstable Angina
Mariaelena Lombardi, Luigi M. Biasucci, Maddalena Piro, Giovanna Di Giannuario, Giulia 
Aguzzi, Sonia Iacovella, Giovanna Liuzzo, Filippo Crea, Institution of Cardiology. Catholic 
University, Rome, Italy
Background: A growing body of evidence supports the patophysiological role of renin-
angiotensin-system (RAS) in the athero-trombotic process, in cardiac remodelling and in
apoptosis. Angiotensin II (AgII) blockade seems to be able to reduce the progression of
atherosclerotic lesion, through an anti-inflammatory mechanism. A reduction of coronary
events has also been observed in trials with these classes of drugs. Therefore we evalu-
ated whether Irbersartan (a selective AgII blocking agent) may modulate the inflamma-
tory response in unstable angina (UA). Methods: We studied 25 UA (Braunwald’s class
IIIB) patients (pts) without hypertension, diabetes, heart failure. Patients were treated
with full conventional anti-ischemic therapy (i.v. nitrates, aspirin, clopidogrel, β -blockade,
statins, low molecular weight-heparin) except Angiotensin Converting Enzyme-inhibitors
and/or AgII inhibitors. Pts were divided into two groups of treatment: group 1 receiving
Irbesartan (300 mg/die) on the top of conventional treatment and group 2 receiving con-
ventional treatment and placebo. Patients were discharged with aspirin, clopidigrel, β -
blocking agents plus Irbesartan (group 1) or placebo (group 2). In all patients we mea-
sured High Sensitivity-CRP levels (Dade-Behring) at Coronary Care Unit entry and after
1 and 3 months of follow up. Results: At entry, CRP levels (median and range) were sim-
ilar in group 1 and group 2 (3.1; 0.7-17.7 and 2.5; 1.1-21.9 mg/L). In group 1, CRP signif-
icantly decreased after 1 and 3 months of follow up, being respectively 1.2 mg/L; 0.16-
10.07 and 0.86; 0.58-4.17 mg/L (P=0.038 versus entry), whereas no changes were
observed in group 2 (2.25; 0.99-4.09 and 1.57;0.22-5.75 mg/L at 1 and 3 months respec-
tively). Conclusions: Our data demonstrate that Irbesartan has an in vivo antinflamma-
tory effects as shown by reduction of CRP levels in patients receiving full medical
therapy, including statins,and after only one month of treatment. Our data suggest a role
for AgII inhibitors in plaque stabilization and may help to explain the reduction of coronary
events in patients treated with AgII Inhibitors.
1160-197 Decreased Serum Ghrelin and Insulin-Like Growth 
Factor-I Levels Associated With Insulin Resistance in 
Patients With Acute Heart Failure: Analysis by Steady-
State Plasma Glucose Method
Satoshi Yasuda, Shunichi Miyazaki, Hiroshi Hosoda, Noritoshi Nagaya, Munetake 
Kanda, Masaaki Hasegawa, Yutaka Harano, Yoichi Goto, Hiroshi Nonogi, Kenji Kangawa, 
National Cardiovascular Center, Osaka, Japan
Background: Ghrelin, a novel and key peptide of energy homeostasis, is associated with
the growth hormone – insulin-like growth factor (IGF)-I axis. Previous studies demon-
strated that IGF-I plays a role in pathogenesis of heart failure (HF), in which metabolic
abnormalities such as insulin resistance may be induced. Thus, the present study was
designed to investigate the role of insulin resistance and its relation with ghrelin and/or
IGF-I in patients with HF.
Methods: We studied 14 patients; seven healthy control subjects (M/F=4/3, age: 62±4
[mean±SD] years), and seven patients with acute HF (NYHA class IV), without diabetes
mellitus or obesity (M/F=5/2, age: 63±11 years). Insulin sensitivity was assessed at 1
week and 3-6 months following acute HF by the steady-state plasma glucose (SSPG)
method using a somatostatin derivative, octreotide acetate. Blood samples were col-
lected to measure the levels of ghrelin and IGF-I. Serum ghrelin level was measured by
newly developed enzyme immunoassay system.
Results: In comparison with the control (76±8 mg/dl), the SSPG level in HF patients was
significantly increased at 1 week (118±30 mg/dl, P<0.01), indicating insulin resistance.
However, at 3-6 months following acute HF, the SSPG level was restored to the control
level (80±21 mg/dl) with the significant increase in serum ghrelin (from 12±6 to 29±28
fmol/mL, P<0.05) and IGF-I levels (from 106±17 to 122±18 ng/mL, P<0.05). In patients
with HF, ghrelin level correlated inversely with insulin resistance (R=-0.625, P<0.01) and
positively with IGF-I level (R=0.675, P<0.01).
Conclusions: In patients with acute HF, insulin resistance is induced in association with
decreased ghrelin and IGF-I levels. The present findings suggest a potential interaction
between the ghrelin-IGF-I system and glucose metabolism by insulin, which may contrib-
ute to pathophysiology of HF.
POSTER SESSION
1161 
Genes, Molecules, and Hypertension
Tuesday, March 09, 2004, 3:00 p.m.-5:00 p.m.
Morial Convention Center, Hall G
Presentation Hour: 3:00 p.m.-4:00 p.m.
1161-171 Blood Pressure Response to Strength Training Is 
Influenced by AGT (-20) Genotype in the Elderly
Anish Meerasahib, Ben Hurley, G. Martel, Steve Roth, University of Maryland,College 
Park, College Park, MD
Background: Several linkage and association studies support the role of the Angiotensi-
nogen (AGT) gene in the development of essential hypertension. The C/A polymorphism
at -20 position has been shown to modify the expression of AGT, which can elevate BP
by raising blood levels of AGT. The purpose of the investigation was to study the relation-
ship of AGT (-20) genotype with resting BP response to Strength Training (ST) in middle-
aged to older adults.
Methods: Fifty-five sedentary, healthy men and women who were homozygous for ade-
nine allele (A/A, n=37, 21 men & 16 women) or heterozygous (A/C, n=18, 11 men & 7
women) at AGT gene locus were enrolled in the study. All subjects went through three to
six months of ST done 3 days per week using Keiser air-powered variable resistance
exercise machines, each session lasting for approximately 45 minutes. One-repetition
maximum (1RM) strength, Body Fat (%) and Fat Free Mass were measured before and
after the ST program. Resting Systolic and Diastolic BP were measured on six separate
occasions before and after ST for each subject. AGT genotyping was performed from
each subject's genomic DNA.
Results: Significant training induced reductions were noticed in systolic BPs of female
subjects, which dropped from 123.4 ± 11.3 mm Hg to 120.1 ± 11.4 mm Hg (P<0.05). The
male subjects dropped their diastolic BPs from 77.2 ± 7.9 mm Hg to 75.0 ± 7.1mm Hg
(P<0.05). When analyzed using ANCOVA, accounting for the genotype and the differ-
ences in pre-systolic BP between the two genotypes, the change in systolic BP was sig-
nificantly greater in AA genotype than AC/CC genotype. Systolic BP in AA genotype
dropped from 128.2 ± 2.0 mm Hg to 123.8 ± 1.6 mm Hg (P<0.05), while AC/CC genotype
dropped their systolic BP from 121.0 ± 2.5 mm Hg to 119.8 ± 3.2 mm Hg (P<0.05). When
controlled for the differences in pre-diastolic BP between the two genotypes, the change
in diastolic BP was not significantly different between the two genotypes.
Conclusion: AGT (-20) genotype influences resting blood pressure response to strength
training such that training reduces systolic BP in homozygotes to a more degree than that
in heterozygotes.
1161-172 Upregulation of Akt and Endothelial Nitric Oxide 
Synthase Induces Vascular Smooth Muscle Cell 
Differentiation in Hypertension In Vivo
Shinji Kawahara, Seiji Umemoto, Masakazu Tanaka, Kyoko Umeji, Ryo Hashimoto, 
Susumu Matsuda, Masunori Matsuzaki, Yamaguchi University Graduate School of 
Medicine, Ube,Yamaguchi, Japan
Background Recent studies have shown that angiotensin II type 1 (AT1) receptor-medi-
ated Akt activation induced vascular smooth muscle cell (VSMC) dedifferentiation in vitro.
However, the critical signal transductions affecting the VSMC phenotype remain unclear
in vivo. We examined which signal transduction acting through the AT1 receptor could
regulate the VSMC phenotype in SHRSP in vivo. Methods and Results- Male stroke-
prone hypertensive rats (SHRSP) were randomized and treated for 6 weeks with a vehi-
cle (n=20), an AT1 receptor antagonist (E4177; 30 mg/kg/day, n=20), or an angiotensin-
converting enzyme (ACE) inhibitor (cilazapril; 10 mg/kg/day, n=20). Protein expressions
were analyzed by immunoblots, and NAD(P)H oxidase activity measured by lumines-
cence assay. Both drugs showed equipotent effects on blood pressure, aortic morphol-
ogy, collagen deposition, p38 mitogen-activated protein kinase and p42/44 extracellular
signal-regulated kinase expression in the aorta (P<0.05 vs. the vehicle group, respec-
























tively). The SHRSP group had 12-fold higher levels of total aortic reactive oxygen species
(ROS) assessed by 8-iso-PGF2α, and 4-fold increase in superoxide content assessed by
hydroethidine staining of the aortic media. Both drugs significantly reduced ROS and
NAD(P)H oxidase essential subunit p22phox and its activity (P<0.05), whereas p-Akt,
eNOS, and the contractile-type smooth muscle myosin heavy chain SM2 were signifi-
cantly increased in SHRSP aorta (P<0.01). In addition, E4177 was more effective at
inducing VSMC differentiation by a 43% reduction of ROS through the downregulation of
NAD(P)H oxidase activity, and the upregulation of p-Akt by 27%, eNOS by 32%, and
SM2 by 34% compared with cilazapril respectively (P<0.05). Conclusions- An ACE
inhibitor and an AT1 receptor antagonist inhibited VSMC dedifferentiation through the
reduction of ROS by inhibiting NAD(P)H oxidase, and the upregulation of eNOS and Akt
in SHRSP aorta; suggesting that, in contrast to the results from in vitro experiments,
eNOS and Akt activation through the inhibition of AT1 receptor might be crucial determi-
nants for VSMC differentiation in hypertension in vivo.
1161-173 Stromelysin-1 (MMP-3) Gene 5A/6A Promoter 
Polymorphism Is Associated With Blood Pressure in a 
Community Population
John Beilby, Joseph Hung, Caroline Chapman, Brendan McQuillan, Peter Thompson, Sir 
Charles Gairdner Hospital, Perth, Australia, PathCentre QEII Medical Center, Perth, 
Australia
Background: Vascular remodelling of large and small arteries contributes to the devel-
opment of hypertension. Stromelysin-1, a member of the matrix metalloproteinase
(MMP) family may contribute to arterial remodelling. The expression of stromelysin-1
gene is partly regulated by a common polymorphism in the promoter region of either five
or six consecutive adenosine bases (5A/6A) that alter transcription factor binding.
Methods: A cross-sectional study of 1,111 randomly selected community subjects (553
males and 558 females), age 27-77 years, who were assessed for conventional cardio-
vascular risk factors and the stromelysin-1 5A-1171/6A genotype. Mean common carotid
intima-medial wall thickness (IMT) and presence of plaque was determined by carotid
ultrasound.
Results: The frequency of the stromelysin-1 -1171/5A allele was 0.45. Univariate analy-
sis demonstrated an association between the stromelysin-1 5A-1171/6A genotype and
blood pressure in the whole population. Multivariate analysis showed an independent
association between the stromelysin-1 genotype and systolic and diastolic blood pres-
sure (both P<0.005) in the whole sample. When the population was split by smoking sta-
tus, an independent association with systolic blood pressure (P<0.0001) and diastolic
blood pressure (P=0.006) was present only in smokers. Subjects who smoked and car-
ried the 5A/5A genotype had a higher mean systolic (+6.0 mmHg) and diastolic (+2.5
mmHg) blood pressure compared to 5A/6A and 6A/6A carriers. The association between
the stromelysin-1 genotypes and blood pressure was recessive with the effect only seen
with the 5A/5A genotype. Multivariate analysis in the whole population showed there was
no association with mean IMT (P=0.42) or the likelihood of carotid plaque formation
(P=0.08).
Conclusions: In this large randomly selected, cross-sectional population, the 5A/5A
variant in the stromelysin-1 gene promoter was independently associated with increased
blood pressure in the whole population and in smokers but was not associated with either
increased carotid IMT or plaque formation.
1161-174 Pulse Pressure and Interactions Between 
Polymorphisms in the Angiotensin II Type 1 Receptor 
and Uncoupling Protein 1 Genes in Hypertensive Hong 
Kong Chinese
Yu-Jing Fang, Cai-Xia Li, Ji-Qian Fang, G Neil Thomas, Brian Tomlinson, Chinese 
University of Hong Kong, Hong Kong, People's Republic of China, Sun Yat-Sen 
University, Guangzhou, People's Republic of China
Background: Hypertension and obesity are strongly inter-related and have multifactorial
genetic and environmental components. The angiotensin II type 1 receptor (AT1R) is
involved in the regulation of blood pressure and polymorphisms in this gene have been
implicated in the development of hypertension. The uncoupling protein 1 (UCP1) is solely
expressed in brown adipose tissue and genetic polymorphisms affecting this may be
associated with obesity. The present study was performed to assess the contribution of
polymorphisms of these two genes on blood pressure or obesity parameters in a family
study.
Methods: We studied members of 96 families with a hypertensive proband, including 282
siblings, of which 133 were hypertensive and 144 were obese. Blood pressure, pulse
pressure, body mass index (BMI) and waist:hip ratio (WHR) were recorded for each sib-
ling. The AT1R gene A1166C polymorphism and the UCP1 gene A-3826G polymorphism
were identified with polymerase chain reaction based RFLP protocols. A multi-level
mixed linear model for quantitative trait locus (QTL) analysis was applied to identify
whether these genetic polymorphism loci were related to blood pressure, pulse pressure
or body weight.
Results: No significant association was found between the AT1R and UCP1 gene poly-
morphisms and systolic or diastolic blood pressure. Age and the BMI/WHR ratio were
strongly related to the systolic blood pressure (p<0.0001), diastolic blood pressure
(p<0.0001) and pulse pressure (p=0.0003). Gender was only related to pulse pressure
(p=0.0003). For the AT1R and UCP1 gene polymorphisms, the QTL analysis showed that
the AT1R gene A1166C polymorphism was related to pulse pressure after adjustment for
age, gender and BMI/WHR ratio (p=0.038). A significant gene-gene interaction for pulse
pressure was found between the two gene polymorphisms after adjustment for age, gen-
der and BMI/WHR ratio (p=0.031).
Conclusions: Genetic variation at the AT1R gene locus may modify the risk for developing
abnormal pulse pressure. An interaction between the AT1R genotype and UCP1 geno-
type suggests these loci may be important in determining abnormal blood pressures in
relation to obesity.
1161-175 Platelet-Derived Vascular Endothelial Growth Factor in 
Patients With Hypertension: Relationship to Platelet 
Activation and Plasma Indices of Angiogenesis
Sunil K. Nadar, Graham J. Caine, Andrew D. Blann, Gregory YH Lip, City Hospital, 
Birmingham, United Kingdom
Aims: Platelet activation is an important part of the pathogenesis of complications in
hypertension (HT). Hypertension is also associated with abnormal angiogenesis. We
hypothesise a relationship of platelet derived Vascular Endothelial Growth Factor (VEGF)
to plasma markers of angiogenesis (VEGF, Angiopoietin (Ang)-1 and 2, and Ang receptor
Tie-2) and platelet activation (soluble P-selectin) in hypertension.
Methods: We studied 199 (151 male, mean age 67+ 9 years) patients with HT and 59
normotensive controls( 41 male; mean age 68+11 years). Plasma levels of angiogenesis
such as VEGF, Ang-1, and Ang2, and Tie-2 were determined by ELISA. Platelet derived
VEGF was measured by lysing a fixed number of platelets, and measuring the levels in
the lysate so obtained.
Results: Plasma indices were abnormal in HT versus controls [Table1]. Platelet derived
VEGF did not vary with the use of aspirin or antihypertensive agents. Platelet derived
VEGF correlated with plasma levels of VEGF( Spearmans r=0.257, p=0.001), Ang 1
(r=0.307, p=0.001) and Tie 2 (r=0.19 p=0.007), but not with soluble p-selectin.
Conclusions: Hypertensive patients have raised platelet derived VEGF which correlates
with the plasma levels of VEGF and Ang-1. This suggests a role for platelets in the abnor-
mal angiogenesis that is seen in hypertension
1161-176 Carvedilol Reduces Serum Concentration of DNA-
Damage Biomarker 8-Hydroxydeoxyguanosine in 
Human Hypertension
Juyong Lee, Mejeong Lee, Jung-Wook Kim, Jin-Geun Jang, Yoon-Suck Choi, Sang-Sig 
Cheong, Gangneung Asan Hospital, Gangneung-si, South Korea
Background: Oxidative DNA damage due to reactive oxygen species(ROS) has been
implicated in cardiovascular diseases. Deoxyguanosine is one of the constituents of DNA
and when it is oxidized, it is altered into 8-OHdG. The serum concentration of the DNA
repair product 8-OHdG has been proposed as a noninvasive biomarker of oxidative DNA
damage in human in vivo. Carvedilol has shown to have antioxidant actions in patients by
reduction of anti-oxidized LDL antibodies and to reduce ROS in normal human subjects.
However, there has been no data that carvedilol reduce DNA damage in human hyper-
tension. Methods: Seventeen newly diagnosed hypertension patients (mean age
=51±11, male/female=11/6) who have not taken antihypertensive medication previously
volunteered for the study. Fasting blood sample were collected at baseline in tubes with
EDTA as an anticoagulant. The subjects were given 12.5 or 25 mg of carvedilol PO once
a day for 2 months. Two months later, another blood sample was collected as above. Age
and sex matched control subjects (n=22, mean age =45±12, male/female=14/8), not
given any drugs, also had 2 samples taken 2 months apart. None of the subjects were on
any medications, including NSAIDs, Vitamin E, or other antioxidants. Serum 8-OHdG
was measured with ELISA method. High sensitivity C-reactive protein (hs-CRP) was also
checked two times. There were no statistical differences in smoking, diabetes, and total
cholesterol level between hypertension and control group. Results: In the hypertension
group, DNA damage biomarker 8-OHdG at baseline was 9.07±4.23 ng/ml (mean±SD).
After carvedilol administration, it fell to 5.74±3.89 ng/ml (p=0.002). In the control group,
the 8-OHdG concentrations were 3.41±2.03, 3.01±2.65 ng/ml at baseline and 2 months
later, respectively (p=NS). The baseline 8-OHdG was higher in the group of hypertension
than in control(p=0.001). hs-CRP had no significant difference before and after carvedilol
treatment in the hypertension group( 0.21±0.51, 0.19±0.37 mg/dl). Conclusion: DNA
damage due to ROS occurs more in hypertension patients than in normal blood pressure
people. Carvedilol may significantly reduce DNA damage in hypertension patients.
1161-177 Modulatory Effect of Inflammation on Blood Pressure 
Reduction Following Therapeutic Lifestyle Change via 
Cardiac Rehabilitation and Exercise Training
Richard V. Milani, Carl J. Lavie, Ochsner Clinic Foundation, New Orleans, LA
Background: Inflammation promotes the development and progression of atherosclerosis
and is associated with several traditional CV risk factors including hypertension, diabe-
tes, and dyslipidemia. We evaluated the impact of inflammation on improvement in risk
factors following 12 weeks (36 sessions) of therapeutic lifestyle change (TLC) via cardiac
rehabilitation and exercise training (CRET) in 635 patients (mean age 64.6 ±10.7 years)
4-6 weeks following a major CHD event.
Methods: Patients were dichotomized based upon baseline median hs-CRP (median =
3.2 mg/L) values. At baseline there were no differences in age, gender, systolic and dias-
Controls (n=59) Hypertensive (n=199) p-value
SBP (mmHg) 130(9) 147(22) 0.001
DBP (mmHg) 80 (9) 80(11) 0.9
s P-selectin (ng/ml) 77(38-110) 150(106-213) <0.001
VEGF (ng/ml) 500(42-7750) 1500(30-100000) <0.001
Ang-1 (ng/ml) 10(6-60) 700(250-1300) <0.001
Ang-2 (ng/ml) 1.8(0.5-3.0) 1.8(1.1-3.5) 0.01
Platelet VEGF (ng/ml) 30 (10-200) 600(50-3000) <0.001
